PCRX DEADLINE NOTICE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Pacira BioSciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 14 Deadline in Securities Class Action
SO WHAT: If you purchased Pacira securities during the Class Period, you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Pacira class action, go to https://rosenlegal.com/submit-form/?case_id=33570 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 14, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, statements made during the Class Period were false and/or misleading because defendants created the false impression that Pacira had sufficient patent protections on Exparel and, as such, the ability to expand the marketing, production, and sales of Exparel, which Pacira stated was critical to its future growth and revenue. In truth, Pacira's optimistic claims pertaining to its patent protections on Exparel were fragile at best. In fact, Pacira knew that the '495 patent was not as protective as defendants publicly touted because on June 6, 2023 the New Jersey District Court issued a ruling in eVenus's favor regarding claims construction in another case filed by Pacira in a failed attempt to protect Exparel. Yet defendants continued to make public statements affirming their belief in the '495 patent and the protection it applied for Exparel. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Pacira class action, go to https://rosenlegal.com/submit-form/?case_id=33570 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Arrowhead (ARWR) Climbs 24.9% on $100-Million Licensing Revenue
We recently published . Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is one of the last week's top performers. Arrowhead Pharmaceuticals soared by 24.9 percent week-on-week as investors welcomed the company's receipt of $100 million in payments from Sarepta Therapeutics Inc. (NASDAQ:SRPT) in relation to a licensing agreement previously entered into. Of the total amount, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) said $50 million was redeemed in the form of shares, while the remaining $50 million was received in cash. Investors particularly cheered the election to place the redeemed stocks into the treasury, effectively reducing its total outstanding shares and boosting the value of existing shares. 'We are committed to supporting our broad and long-term collaboration and we are thrilled with the great progress we've made on multiple important clinical, preclinical, and discovery stage siRNA programs. While we remain confident that Sarepta will meet its financial obligations to Arrowhead, we believe reducing our outstanding shares by receiving approximately half of the $100 million due from Sarepta in cash and half in Arrowhead stock to be returned to treasury is a compelling opportunity,' Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) President and CEO Christopher Anzalone said. Copyright: dolgachov / 123RF Stock Photo The payments were made in satisfaction of Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) achievement of the first of two pre-specified enrollment targets in relation to an early-stage clinical trial for the study of ARO-DM1, a therapy candidate for type 1 myotonic dystrophy (DM1). Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) said that any subsequent milestones earned will continue to be payable in cash. While we acknowledge the potential of ARWR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New York Post
14 minutes ago
- New York Post
OpenAI CEO Sam Altman warns of AI bubble, says investors are ‘overexcited': report
OpenAI CEO Sam Altman warned that the billions of dollars being plowed into the artificial intelligence arms race risks causing a bubble comparable to the dot-com crash of the early 2000s. 'When bubbles happen, smart people get overexcited about a kernel of truth,' Altman said during a dinner with a group of journalists, The Verge reported on Friday. 'Are we in a phase where investors as a whole are overexcited about AI? My opinion is yes. Is AI the most important thing to happen in a very long time? My opinion is also yes.' Advertisement 4 OpenAI CEO Sam Altman testifies before a Senate Committee on Commerce, Science and Transportation. AP Altman likened the AI funding rush to 'the tech bubble,' when investors 'got overexcited' about internet-based companies in the late 1990s. Between March 2000 and October 2002, the Nasdaq lost nearly 80% of its value after many of these online companies failed to turn a profit. Advertisement In a report released last month, Torsten Slok, head economist at Apollo Global Management, argued that the AI bubble is actually bigger than the internet bubble, with the top 10 companies in the S&P 500 more overvalued than they were in the late 1990s. Ray Wang, research director for semiconductors, supply chain and emerging technology at Futurum Group, took a more optimistic stance. 'From the perspective of broader investment in AI and semiconductors… I don't see it as a bubble. The fundamentals across the supply chain remain strong, and the long-term trajectory of the AI trend supports continued investment,' he told CNBC in a statement. However, there is a high amount of speculative capital being thrown at companies who only have perceived potential – which could lead to pockets of overvaluation, Wang added. Advertisement 4 OpenAI chief Sam Altman likened the AI funding rush to the internet bubble of the early 2000s. REUTERS 'Calling it a bubble is too simplistic. What we're really seeing is a supply chain bottleneck – too much capital with real need, chasing too little compute,' Kyle Okamoto, chief technology officer at Aethir, a decentralized cloud GPU network, told The Post on Monday. 'Until infrastructure catches up, prices and hype will stay inflated, but that's not a bubble bursting – that's a market maturing.' Fears that the US might be in an AI bubble grew earlier this year after the explosive rise of DeepSeek, a Chinese tech firm that claimed to make a competitive AI model with a fraction of the time and money it took American rivals. Advertisement DeepSeek said its AI chatbot had been trained for under $6 million, far below the billions spent by US counterparts. OpenAI is on track to pass $20 billion in annual recurring revenue but it remains unprofitable, Altman said earlier this month. 4 OpenAI is on track to pass $20 billion in annual recurring revenue, but it remains unprofitable, according to Altman. AFP via Getty Images Its recent launch of ChatGPT-5 was so disappointing that customer complaints pushed the company to go back to the drawing board while reverting to the GPT-4 model. During the dinner with reporters, Altman said the term artificial general intelligence, or 'AGI,' is losing its relevance. AGI refers to a form of AI that can perform any intellectual task that a human can – which Altman previously said could be achieved in the 'reasonably close-ish future.' Altman's startup continues to draw in big investments. In March, OpenAI raised $40 billion at a $300 billion valuation – far above the largest amount ever raised by a tech company. Advertisement It now is preparing to sell around $6 billion in stock at roughly a $500 billion valuation. 4 Sam Altman jabbed at rival Elon Musk's Grok chatbot. REUTERS Altman said that he expects OpenAI to spend trillions of dollars on data center expansions. He has also expressed interest in buying Chrome if the US government forces Google to sell off the web browser as part of an antitrust case. Advertisement Separately, Altman confirmed reports that OpenAI is planning to launch a brain-computer interface startup similar to Elon Musk's Neuralink – and took a jab at his rival's firm xAI. 'You will definitely see some companies go make Japanese anime sex bots because they think that they've identified something here that works,' Altman said in a dig at Musk's Grok chatbot. 'You will not see us do that. We will continue to work hard at making a useful app, and we will try to let users use it the way they want, but not so much that people who have really fragile mental states get exploited accidentally.'
Yahoo
32 minutes ago
- Yahoo
Yext, Duolingo, Applied Digital: Trending Tickers
Yext (YEXT) stock is climbing after CEO Michael Walrath proposed taking the company private in a $1.1 billion deal. Duolingo (DUOL) was upgraded to Overweight from Sector Weight by Keybanc, despite recent backlash from artificial intelligence (AI) and viral marketing efforts. Applied Digital (APLD) stock is surging after the company announced plans for a $3 billion AI-focused data center campus in September. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts. Now time for some of today's trending tickers. We are watching Yext, Duolingo and Applied Digital. First up, Yext. Shares jumping as its CEO proposed taking the company private. The CEO proposing to take the search optimization company private in a deal valued at about $1.1 billion. It's Michael Walroth. He indicated that the proposal is backed by reputable and well capitalized financing sources, but didn't disclose the names of those sources. So with us senior reporter Brooke DiPalma from the Nasdaq. So seeing those shares get a boost on that, um, and you know, as always, we don't know how these situations exactly if it's gonna end up going through. Absolutely. It's worth noting that right now they would buy it out of that $9 price point, that's where it's trading at. But that's largely just a tin lower than it's 52 week high of $9.16. Also worth noting that the attention from the street has been quite minimal when it comes to coverage here. Yext has three buy ratings, one hold and that's about all the coverage that they're getting right now from the street, but it's also, you know, remains to be seen what exactly happens. We know that they're set to release their fiscal year 2026 second quarter earnings in early September. They also withdrew their guidance for the rest of the year and so I think investors are just sort of in that wait and see mode. Certainly you see some momentum at that price point of $9 per share, but over the past month, this momentum, you know, right now largely gaining a lot because of this today's trading action. In the past six months though, we have seen this stock move up about 35% after it got a bit of a boost back in June. And next up, let's talk Duolingo, Brooke, getting an upgrade at KeyBank. The analyst upgrading the language learning software company to overweight from sector weight, saying that the AI backlash was a bump in the road, viral marketing efforts have created upside risk and the company's CEO has been out talking a lot about AI. So and seeing a little bit of a bumpiness on that that the analyst alluded to, but today up 10 and a half percent. Yeah, they did get a city initiating coverage of Duolingo with a buy and there is lots of optimism on the street when it comes to this stock. We have 18 buy ratings, as well as seven holds once again, including that city initiating coverage with a price target set to $400. Now this stock is right now priced around $361 and that's really kind of in the middle of their 52 week high and 52 week low being $201, 52 week high being $554. But it's also worth noting that New York Times did have an interview with the CEO over the weekend and he did weigh in on that backlash that they got after they did send out that memo around AI and he said that this one was a me. I did not give enough context internally, it was not controversial. And he went on to say that external is a publicly traded company. Some people assume that it's just for profit or that we're trying to lay off humans and that was not their intent at all. And so it'll be interesting to see how this language machine really does use AI in the coming years for, you know, not only for their employees and boosting that productivity there, but also for users as well. Yeah. And I'm sure it's not going to be the last company dealing with that kind of trying to to tread that line carefully. Uh but finally let's talk about Applied Digital, announcing it's going to break ground on a $3 billion campus next month. That new campus designed to meet surging demand for computing power. The shares are up 14 and a half percent today. This one feels a little memey, I got to say, when you look at the action that we have sort of seen in the stock, it's more than doubled year to date, Brooke. Yeah, and right now it's trading around that 52 week high of $16.92. But then keep in mind on the flip side, it's 52 week low was just $3. And so I really think this speaks volumes to what we've seen around that excitement of AI. It largely seems especially what we heard during earnings reports and rather the market reaction to earnings beats and any sort of mention of AI has been this flock, this excitement among investors that this is really going to change the game, but as you could see here, it's been sort of a short, a short high and then you know, a really fall to $3 over the past 52 weeks. Important to note here that they also did announce this back in, you know, they announced this today, but also back in June, they also entered an agreement with core weave. And so I think this company has really just been looped into this AI narrative and this excitement that investors have around that right now. Yeah, it looks that way. Thanks a lot, Brooke. You can scan the QR code below to track the best and worst performing stocks with Yahoo Finances trending tickers page. Related Videos GoodRx CEO discusses GLP-1 deal with Novo Nordisk: What to know Trump to meet Zelensky at WH: US vs. European defense stocks Solar stocks, Tesla, TeraWulf & Google: Trending Tickers Air Canada, Soho House, Dayforce: Trending Tickers Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
